These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 21689488)
1. Developments in MS over the Past 17 Years the MS Forum and The International MS Journal. Bates PD; Jacobson S Int MS J; 2011 Sep; 17(3):75. PubMed ID: 21689488 [TBL] [Abstract][Full Text] [Related]
2. Modern multiple sclerosis treatment - what is approved, what is on the horizon. Pilz G; Wipfler P; Ladurner G; Kraus J Drug Discov Today; 2008 Dec; 13(23-24):1013-25. PubMed ID: 18775508 [TBL] [Abstract][Full Text] [Related]
3. Mitoxantrone: a review of its use in multiple sclerosis. Scott LJ; Figgitt DP CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110 [TBL] [Abstract][Full Text] [Related]
4. Interferons in MS Treatment: report from the Canadian MS Forum symposium, 26-29 August 2004, Québec, Canada. Duquette P Int MS J; 2005 Apr; 12(1):33-4. PubMed ID: 15955277 [TBL] [Abstract][Full Text] [Related]
5. Promoting remyelination in multiple sclerosis: current drugs and future prospects. Kremer D; Küry P; Dutta R Mult Scler; 2015 Apr; 21(5):541-9. PubMed ID: 25623245 [TBL] [Abstract][Full Text] [Related]
7. Neuroprotection in multiple sclerosis report from the MS Forum 16th Modern Management Workshop, March 2004, Cernobbio, Italy. Hohlfeld R; Kappos L Int MS J; 2004 Sep; 11(2):61-3. PubMed ID: 15279736 [TBL] [Abstract][Full Text] [Related]
8. Cannabinoids in multiple sclerosis: do they have a therapeutic role? Killestein J; Uitdehaag BM; Polman CH Drugs; 2004; 64(1):1-11. PubMed ID: 14723555 [TBL] [Abstract][Full Text] [Related]
9. Drug companies offer DM programs for MS patients. Dis Manag Advis; 2002 Nov; 8(11):165-8, 161. PubMed ID: 12506456 [TBL] [Abstract][Full Text] [Related]
10. Therapeutic Application of Monoclonal Antibodies in Multiple Sclerosis. Orthmann-Murphy JL; Calabresi PA Clin Pharmacol Ther; 2017 Jan; 101(1):52-64. PubMed ID: 27804128 [TBL] [Abstract][Full Text] [Related]
11. Motivating MS patients: the Annual Convention 2005 of the MS Forum, 22 May 2005, St Julians, Malta. Clanet M Int MS J; 2005 Nov; 12(3):109. PubMed ID: 16417819 [TBL] [Abstract][Full Text] [Related]
13. Axonal degeneration in multiple sclerosis: defining therapeutic targets by identifying the causes of pathology. Lee JY; Biemond M; Petratos S Neurodegener Dis Manag; 2015 Dec; 5(6):527-48. PubMed ID: 26619755 [TBL] [Abstract][Full Text] [Related]
14. A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type. Nikfar S; Rahimi R; Abdollahi M Clin Ther; 2010 Oct; 32(11):1871-88. PubMed ID: 21095482 [TBL] [Abstract][Full Text] [Related]
15. Immunogenicity and tolerability of an investigational formulation of interferon-beta1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis. Giovannoni G; Barbarash O; Casset-Semanaz F; Jaber A; King J; Metz L; Pardo G; Simsarian J; Sørensen PS; Stubinski B; Clin Ther; 2007 Jun; 29(6):1128-45. PubMed ID: 17692727 [TBL] [Abstract][Full Text] [Related]
17. MS Across Continents: Challenging our Knowledge of MS in Asia and the Middle East. Report from the 2nd MS Forum Pan-Asian Conference, 19-20 November 2004, Ho Chi Minh City, Vietnam. Fujihara K; Ong BK Int MS J; 2005 Apr; 12(1):34-5. PubMed ID: 15955278 [TBL] [Abstract][Full Text] [Related]
18. [Disease-modifying drugs in pediatric patients with multiple sclerosis]. Bykova OV; Nankina IA; Drozdova IM; Kvasova OV; Batysheva TT; Boiko AN Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(2 Pt 2):44-53. PubMed ID: 27070361 [TBL] [Abstract][Full Text] [Related]